Founded in 2024, Lumonus offers an AI-native clinical care platform that streamlines end-to-end radiation oncology workflows. Its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, enable clinicians to consult and prescribe on cancer treatments more efficiently. The software is already deployed across the United States, Australia and Europe, where care teams have used it in more than 280,000 cancer treatment consultations and to automate over 75,000 treatment plans. With fresh funding, the company plans to expand its U.S. go-to-market and clinical success teams, bolster its clinical informatics capabilities, and further personalize its AI tools. Lumonus positions itself as a partner to oncology teams seeking data-driven, workflow-centric solutions. Financially, the startup has raised a total of $28 million in Series B financing, following a seed round backed by Oncology Ventures in March 2025.

Total raised

$19M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2026